Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmaceutics ; 16(1)2024 Jan 03.
Article in English | MEDLINE | ID: mdl-38258081

ABSTRACT

Compounds that potentiate the activity of clinically available antibiotics provide a complementary solution, except for developing novel antibiotics for the rapid emergence of multidrug-resistant Gram-negative bacteria (GNB). We sought to identify compounds potentiating polymyxin B (PMB), a traditional drug that has been revived as the last line for treating life-threatening GNB infections, thus reducing its nephrotoxicity and heterogeneous resistance in clinical use. In this study, we found a natural product, sanguinarine (SA), which potentiated the efficacy of PMB against GNB infections. The synergistic effect of SA with PMB was evaluated using a checkerboard assay and time-kill curves in vivo and the murine peritonitis model induced by Escherichia coli in female CD-1 mice in vivo. SA assisted PMB in accelerating the reduction in bacterial loads both in vitro and in vivo, improving the inflammatory responses and survival rate of infected animals. The subsequent detection of the intracellular ATP levels, membrane potential, and membrane integrity indicated that SA enhanced the bacterial-membrane-breaking capacity of PMB. A metabolomic analysis showed that the inhibition of energy metabolism, interference with nucleic acid biosynthesis, and the blocking of L-Ara4N-related PMB resistance may also contribute to the synergistic effect. This study is the first to reveal the synergistic activity and mechanism of SA with PMB, which highlights further insights into anti-GNB drug development.

2.
Clin Chim Acta ; 541: 117240, 2023 Feb 15.
Article in English | MEDLINE | ID: mdl-36736683

ABSTRACT

BACKGROUND: We developed an efficient online automated quality control (AUTO QC) system and tested its feasibility on automatic laboratory assembly lines. METHODS: AUTO QC is based on developed quality control software (Smart QC) and designed adaptable consumables before. We applied the system to two assembly lines in our laboratory. Using third-party quality control samples, we evaluated the impact of the online AUTO QC system on out-of-control rate, biosecurity risk, turnaround time (TAT) and cost. RESULTS: AUTO QC significantly decreased the occurrence rate of the Westgard quality control rules 13S/22S/R4s and 12S, representing out-of-control and warning, respectively. The out-of-control rates were reduced by 58%, and the potential biosecurity risk of the samples decreased by 90%. The AUTO QC implementation also reduced the median TAT (by 7 min), the number of full-time employees and the cost of the quality control samples (by 45%). CONCLUSIONS: The total laboratory AUTO QC system can improve the quality and stability of QC testing and reduce cost.


Subject(s)
Laboratories , Software , Humans , Quality Control
3.
Int J Mol Sci ; 24(3)2023 Jan 18.
Article in English | MEDLINE | ID: mdl-36768218

ABSTRACT

The Zika virus (ZIKV) epidemic poses a significant threat to human health globally. Thus, there is an urgent need for developing effective anti-ZIKV agents. ZIKV non-structural protein 5 RNA-dependent RNA polymerase (RdRp), a viral enzyme for viral replication, has been considered an attractive drug target. In this work, we screened an anti-infection compound library and a natural product library by virtual screening to identify potential candidates targeting RdRp. Then, five selected candidates were further applied for RdRp enzymatic analysis, cytotoxicity, and binding examination by SPR. Finally, posaconazole (POS) was confirmed to effectively inhibit both RdRp activity with an IC50 of 4.29 µM and the ZIKV replication with an EC50 of 0.59 µM. Moreover, POS was shown to reduce RdRp activity by binding with the key amino acid D666 through molecular docking and site-directed mutation analysis. For the first time, our work found that POS could inhibit ZIKV replication with a stronger inhibitory activity than chloroquine. This work also demonstrated fast anti-ZIKV screening for inhibitors of RdRp and provided POS as a potential anti-ZIKV agent.


Subject(s)
Zika Virus Infection , Zika Virus , Humans , Antiviral Agents/chemistry , Molecular Docking Simulation , Zika Virus Infection/drug therapy , Virus Replication , RNA-Dependent RNA Polymerase/metabolism , Biological Assay , Viral Nonstructural Proteins/metabolism
4.
ACS Appl Mater Interfaces ; 14(14): 16204-16213, 2022 Apr 13.
Article in English | MEDLINE | ID: mdl-35363474

ABSTRACT

Lithium cobalt oxide (LCO) as a classic layered oxide cathode for lithium-ion batteries is limited by the cutoff voltage, which only delivers about half of the theoretical capacity (∼4.2 V, 140 mA h g-1). Recently, raising the cutoff voltage to 4.6 V has been considered to further improve its specific capacity. However, LCO suffers from serious phase transition of O3 to H1-3, which leads to dramatic volume change and loss of cobalt, finally resulting in rapid capacity decay. In this work, we introduce the NASICON-structured LiZr2(PO4)3 (LZP), an ion conductor for lithium ion, to modify the surface of LCO by a wet-chemical method. Such a surface modification improves lithium-ion diffusion between the interface of LCO and electrolyte and restrains the O3 to H1-3 phase transition. As a result, the optimized LCO with 1 wt % coating (denoted as LCO@LZP-1%) demonstrates enhanced electrochemical performance in both half-cell and full-cell. To be specific, LCO@LZP-1% delivers a high specific capacity of 161.3 mA h g-1 and increases the capacity retention from 37.8 to 75.1% within 100 cycles. Importantly, the full-cell assembled by LCO@LZP-1% and artificial graphite can exhibit an outstanding energy density of 345.5 W h kg-1 (based on the total mass of cathode and anode).

5.
J Biol Chem ; 280(25): 23490-5, 2005 Jun 24.
Article in English | MEDLINE | ID: mdl-15767249

ABSTRACT

The accumulation of glycochenodeoxycholate (GCDC) induced hepatocyte apoptosis in cholestasis. However, many hepatocytes still survived GCDC-induced apoptosis. The molecular mechanism for the survival of hepatocytes remains unclear. In the present study, isolated rat hepatocytes were cultured in William's E medium and treated with 50 microM GCDC. DNA, RNA, cell lysate, and nuclear proteins were collected at different intervals for DNA fragmentation assay, reverse transcription PCR, Western blotting, and gel mobility shift assay, respectively. GCDC-induced active caspases were detected as early as 2 h by Western blotting and kinetic caspase assay, whereas hepatocyte apoptosis was found at 4 h by DNA fragmentation and terminal deoxynucleotidyl transferase-mediated dUPT nick-end labeling assay. When GCDC was removed, the increased caspases as well as NF-kappaB could be restored to control level. A1/Bfl-1 and inducible nitric oxide synthase (iNOS) were up-regulated in 2 h of GCDC stimulation. After GCDC was removed, hepatocytes decreased expression of A1/Bfl-1, but not iNOS, to the control level. NF-kappaB activation coincided with the change of A1/Bfl-1. Survivin, cIAP1, cIAP2, XIAP, and A1/Bfl-1, but not iNOS, were down-regulated by pan-caspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone. In addition, benzyloxycarbonyl-VAD-fluoromethyl ketone inhibited release of cytochrome c and suppressed NF-kappaB activation. Our data suggested that caspase pathway is an important regulatory factor during hepatocyte apoptosis. GCDC-induced caspase response is reversible, which may activate anti-apoptotic genes to protect hepatocytes from apoptosis.


Subject(s)
Apoptosis/drug effects , Caspases/metabolism , Hepatocytes/drug effects , Amino Acid Chloromethyl Ketones/pharmacology , Animals , Apoptosis/genetics , Base Sequence , Caspase Inhibitors , Cysteine Proteinase Inhibitors/pharmacology , DNA Primers , Enzyme Activation , Hepatocytes/cytology , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction
6.
Xenotransplantation ; 9(1): 36-44, 2002 Jan.
Article in English | MEDLINE | ID: mdl-12005103

ABSTRACT

The aim of this study was to determine if human decay-accelerating factor (hDAF) protects against hyperacute rejection in an ex vivo liver perfusion system using human blood. Pig livers were perfused ex vivo via the portal vein for an average of 5-6 h using a membrane oxygenator. Three groups were studied. Group I: Wild-type pig livers were alloperfused with fresh pig blood (n = 5). Group II: Wild-type pig livers were xenoperfused with fresh human blood (n = 5). Group III: hDAF transgenic pig livers were xenoperfused with fresh human blood (n = 5). The graft ischemic time, ratio of perfusate volume to liver weight, flow rate, and perfusate hematocrit were similar in each group. The hDAF livers perfused with human blood (Group III) had a lower ALT level, less protein and albumin losses, lower bilirubin levels in the perfusate, less weight gain, and greater bile production than the wild-type livers perfused with human blood. Histology showed classic features of hyperacute rejection in Group II, including massive hemorrhage, severe vasculitits, fibrin and C5b-9 deposition, and endothelial damage within 1 h of perfusion, whereas liver histology studies in Groups I and III were near normal. IgG and IgM deposits were seen in the xenoperfused livers. Electron microscopy (EM) and immuno-EM showed loss of endothelial cells, trapping of white blood cells and platelets, and diffuse fibrin deposits in Group II only. hDAF pig livers perfused with human blood showed superior function and histology when compared with wild-type pig livers. These data suggest that (1) hyperacute rejection may contribute to the inconsistent results using wild-type pig livers for extracorporeal liver support and (2) genetically modified pigs that express hDAF may provide a better donor source than wild-type pigs for extracorporeal liver support.


Subject(s)
Blood Transfusion , CD55 Antigens/genetics , Graft Rejection/prevention & control , Liver/physiology , Transplantation, Heterologous/immunology , Animals , Animals, Genetically Modified , Humans , In Vitro Techniques , Organ Preservation , Perfusion/methods , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...